Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Sep;22(3):531–533. doi: 10.1128/aac.22.3.531

Mutation frequency of Haemophilus influenzae to rifampin resistance.

P M Mendelman, M C Roberts, A L Smith
PMCID: PMC183781  PMID: 6982682

Abstract

Twenty-two susceptible strains of Haemophilus influenzae were examined for mutation to rifampin resistance (minimal inhibitory concentration, greater than or equal to 10 micrograms/ml). All strains had detectable apparent mutation frequencies with a median minimal inhibitory concentration 2,000-fold greater than that of their wild-type parents. Of the type b strain mutants, 80% (8 of 10) expressed high-level resistance (minimal inhibitory concentration, 750 micrograms/ml) that was 75-fold greater than readily achievable serum concentrations.

Full text

PDF
531

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Back A. E., Oberhofer T. R. Use of the Minitek system for biotyping Haemophilus species. J Clin Microbiol. 1978 Mar;7(3):312–313. doi: 10.1128/jcm.7.3.312-313.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Catlin B. W., Bendler J. W., 3rd, Goodgal S. H. The type b capsulation locus of Haemophilus influenzae: map location and size. J Gen Microbiol. 1972 May;70(3):411–422. doi: 10.1099/00221287-70-3-411. [DOI] [PubMed] [Google Scholar]
  3. Eickhoff T. C. In-vitro and in-vivo studies of resistance to rifampin in meningococci. J Infect Dis. 1971 Apr;123(4):414–420. doi: 10.1093/infdis/123.4.414. [DOI] [PubMed] [Google Scholar]
  4. Granoff D. M., Daum R. S. Spread of Haemophilus influenzae type b: recent epidemiologic and therapeutic considerations. J Pediatr. 1980 Nov;97(5):854–860. doi: 10.1016/s0022-3476(80)80288-5. [DOI] [PubMed] [Google Scholar]
  5. Kilian M. A taxonomic study of the genus Haemophilus, with the proposal of a new species. J Gen Microbiol. 1976 Mar;93(1):9–62. doi: 10.1099/00221287-93-1-9. [DOI] [PubMed] [Google Scholar]
  6. McCracken G. H., Jr, Ginsburg C. M., Zweighaft T. C., Clahsen J. Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease. Pediatrics. 1980 Jul;66(1):17–21. [PubMed] [Google Scholar]
  7. Michaels R. H., Stonebraker F. E., Robbins J. B. Use of antiserum agar for detection of Haemophilus influenzae type b in the pharynx. Pediatr Res. 1975 May;9(5):513–516. doi: 10.1203/00006450-197505000-00010. [DOI] [PubMed] [Google Scholar]
  8. Murphy T. V., McCracken G. H., Jr, Zweighaft T. C., Hansen E. J. Emergence of rifampin-resistant Haemophilus influenzae after prophylaxis. J Pediatr. 1981 Sep;99(3):406–409. doi: 10.1016/s0022-3476(81)80328-9. [DOI] [PubMed] [Google Scholar]
  9. Nicolle L. E., Postl B., Kotelewetz E., Albritton W., Harding G. K., Bourgault A. M., Ronald A. R. Emergence of rifampin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 1982 Mar;21(3):498–500. doi: 10.1128/aac.21.3.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Postel E. H., Goodgal S. H. Competence mutants. II. Physical and biological fate of donor transforming deoxyribonucleic acid. J Bacteriol. 1972 Jan;109(1):292–297. doi: 10.1128/jb.109.1.292-297.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Roberts M., Stull T. L., Smith A. L. Comparative virulence of Haemophilus influenzae with a type b or type d capsule. Infect Immun. 1981 May;32(2):518–524. doi: 10.1128/iai.32.2.518-524.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Yogev R., Melick C., Glogowski W. In vitro development of rifampin resistance in clinical isolates of Haemophilus influenzae type b. Antimicrob Agents Chemother. 1982 Mar;21(3):387–389. doi: 10.1128/aac.21.3.387. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES